DSIP clinical trials: what the human studies actually show

Last updated 2026-07-26

What is DSIP and why does it have clinical trials at all

DSIP stands for delta sleep-inducing peptide, a nonapeptide (nine amino acids) first isolated from rabbit brain venous blood in 1977 by a Swiss research group led by Schoenenberger and Monnier, who were studying substances that appeared during electrically induced sleep in animals ^[1]. The idea was that this peptide might trigger or support delta wave (slow wave) sleep, the deep stage of non-REM sleep tied to physical restoration. That origin story is why the name still drives interest today. It sounds like a sleep hormone with a mechanism. But isolating a peptide from rabbit blood in the 1970s and running it in a handful of human pilot studies over the following two decades is a very different thing from proving it works as a sleep aid in people. The clinical record reflects that gap directly. Most of what gets cited as DSIP evidence traces back to a short window of research, roughly 1977 through the early 1990s, out of European sleep labs. There is no large-scale, modern, randomized controlled trial in the peptide literature. If you want the full background on the peptide itself, the dsip hub page covers the compound's history and proposed mechanisms in more depth.

What did the original human DSIP sleep studies find

The earliest human work reported effects on EEG delta activity and subjective sleep quality in small samples, not a consistent, reproducible improvement in objective sleep architecture across studies. Schoenenberger and Monnier's foundational reports described DSIP administration alongside changes in sleep-related EEG patterns in humans and animals, but the studies were small, uncontrolled or loosely controlled by modern standards, and often combined multiple endpoints (mood, pain threshold, sleep) in the same short paper ^[1]. A frequently cited follow-up is a study on insomniac patients from the early 1980s, which reported some improvement in sleep patterns after DSIP administration compared to placebo in a small cohort, but with limited statistical power and no replication at scale ^[2]. Later reviews of peptide and sleep research describe DSIP's sleep effects in humans as inconsistent between studies, with some trials finding modest changes in specific sleep stages and others finding no significant difference from placebo ^[3]. The honest summary: several small human trials exist, spread across different countries and labs, using different doses, delivery routes, and outcome measures. That inconsistency alone is a problem. When a compound has a real, reproducible effect on human sleep, later trials tend to converge on similar findings using similar protocols. DSIP's human data doesn't show that convergence.

How many people have actually been studied in DSIP sleep trials

Nobody has run a DSIP sleep trial with more than a few dozen participants, and most of the published human work involves sample sizes in the single digits to low tens. This is a real limitation that gets lost when DSIP is marketed as a researched sleep peptide. Compare that to how modern sleep drug trials are actually run. FDA approval trials for insomnia medications like suvorexant enrolled thousands of patients across multi-site, placebo-controlled, dose-ranging studies before approval ^[4]. DSIP has nothing close to that. The studies that exist are pilot-scale investigations from a research era (1970s-1990s) when peptide and EEG methodology looked very different than it does today, and when small uncontrolled studies were a normal part of hypothesis generation rather than a basis for efficacy claims. A small sample size doesn't automatically mean a finding is wrong. But it does mean the finding is fragile. A study with 8 or 12 subjects can be swayed by a couple of high responders, by placebo effect, by measurement noise in EEG scoring, or by publication bias (positive small studies get published; null small studies often don't). None of the DSIP sleep literature has been scaled up to test whether the early signal holds in a larger, better-controlled population.

Is there a real clinical trial registry record for DSIP

There is no active, completed, and results-reported DSIP trial in ClinicalTrials.gov's contemporary listings that would meet current standards for demonstrating a sleep benefit in humans. Searching the registry for delta sleep-inducing peptide returns essentially nothing from the current trial infrastructure that modern investigational drugs go through ^[5]. This matters because ClinicalTrials.gov, run by the National Library of Medicine, is the standard place where sponsors of new drug and biologic research register US-based human trials, particularly anything moving toward FDA review ^[5]. Its near-absence for DSIP tells you the compound was studied in an earlier academic era, before that registry existed in its current form (it launched in 2000), and has not been picked up by a modern sponsor running a registered trial since. That's different from saying DSIP has been disproven. It means DSIP's evidence sits outside the modern clinical trial infrastructure entirely. There's no Phase 1, Phase 2, or Phase 3 data in the sense that regulators and clinicians use those terms for approved drugs.

Has DSIP been studied for stress or cortisol, more than sleep

Yes, and this line of research is arguably better supported than the sleep claims, though it's still animal-dominant and decades old. Some of the original DSIP work in the late 1970s and 1980s looked at effects on the hypothalamic-pituitary-adrenal (HPA) axis, including reports that DSIP influenced ACTH and cortisol responses to stress in animal models ^[6][3]. There are human reports touching on DSIP and stress hormone regulation, including small studies in clinical populations (for example, in the context of opiate withdrawal or alcohol dependence, where researchers explored whether DSIP could ease withdrawal symptoms) ^[3]. These are separate literatures from the sleep-architecture studies and shouldn't be conflated with proof that DSIP treats insomnia. If anything, the stress-axis angle is a reminder that DSIP was never studied as a single-purpose sleep drug. It was investigated as a multi-system peptide with proposed roles in pain modulation, stress response, and sleep, which is part of why no single trial track ever built the kind of depth of evidence you'd want before calling something proven for one specific use.

Why does DSIP show up in supplement and peptide marketing if the trial data is this thin

The name does a lot of unearned work. "Delta sleep-inducing peptide" sounds like a mechanism-confirmed sleep hormone, and that framing gets repeated by sellers who cite the 1977 discovery paper and a couple of 1980s pilot studies as if that settles efficacy in modern humans. It doesn't. Part of the problem is that DSIP is sold in the US almost exclusively as a research chemical, not as an approved drug or a regulated supplement. There's no FDA-reviewed indication, no FDA-approved dosing, and no FDA safety monitoring for products sold this way. The compound has never completed the kind of trial pathway that, for example, suvorexant or ramelteon went through for insomnia ^[4]. That gap between name and evidence is exactly why this article exists: to separate what the sparse human record actually shows from what the framing implies. If you're evaluating whether to use DSIP at all, read the dsip peptide side effects page before anything else, since safety data is just as sparse as efficacy data.

What does DSIP research look like today

Current DSIP research is almost entirely preclinical (cell and animal studies) or narrow mechanistic work, not new human sleep trials. Searches of recent peptide and sleep literature turn up occasional animal studies on DSIP-related pathways, plus older reviews that keep citing the same 1980s-90s human pilot data because nothing newer exists to cite ^[3]. This is a meaningfully different situation from actively-researched sleep compounds. Orexin antagonists, for instance, have an active modern trial pipeline with published results in peer-reviewed journals within the last decade ^[4]. DSIP does not. If a large, well-controlled human trial were underway, PubMed and ClinicalTrials.gov would show it. They don't. For a reader trying to decide what to make of this, the practical read is: DSIP is a decades-old research peptide with an interesting but unfinished story, not a compound with an active or growing modern human efficacy trial base.

How does DSIP's evidence compare to approved sleep medications

What are the main limitations of the DSIP clinical trial record

Five limitations show up repeatedly across the DSIP human literature, and any honest review has to name them directly. Sample sizes are small, often under 20 subjects per study, which limits statistical power to detect a true effect and increases the chance that reported results reflect noise or responder bias rather than a real population-level effect ^[1][2]. Study designs vary widely across the handful of trials that exist, with different doses, injection routes, timing, and outcome measures, making it hard to pool results or compare studies directly ^[3]. Blinding and placebo control are inconsistent by modern standards; several of the earliest reports predate the kind of carefully controlled double-blind protocol that's now standard for sleep drug trials ^[1]. There's no dose-response data of the depth regulators require, meaning nobody has established an optimal human dose backed by controlled trials, which is part of why dosing information you'll find (including on the dsip dosage page) is drawn from research protocols and anecdotal use rather than an approved label. And there has been no modern replication: the field essentially stopped generating new controlled human trials after the early 1990s, so the evidence base has not grown or been retested with current methodology in three decades.

Does DSIP have any published human safety trial data

Formal, modern human safety trial data for DSIP is limited to the same small, older studies that examined its sleep and stress-hormone effects, not a dedicated large-scale safety and tolerability program. The original human pilot studies reported administration without describing systematic, structured adverse event tracking of the kind expected in a modern Phase 1 safety trial ^[1][2]. That means there is no well-developed human safety database for DSIP in the way there is for an FDA-approved drug, where thousands of patient-years of exposure get tracked through clinical trials and post-market surveillance. What exists are scattered reports within the sleep and stress studies, plus whatever real-world experience has accumulated informally through research-chemical use, which isn't captured in any centralized registry. Anyone considering DSIP should treat the absence of a real safety trial record as a genuine unknown, not a reassurance. Absence of reported harm in a dozen small 1980s studies is not the same as an established safety profile.

So does DSIP actually work for sleep in humans

The honest answer is: the human evidence is too old, too small, and too inconsistent to say DSIP reliably improves sleep in people. Some early studies reported changes in EEG delta activity or subjective sleep ratings after DSIP administration ^[1][2], but these findings haven't been replicated in a large, modern, well-controlled trial, and later reviews describe the human sleep effects as inconsistent across the available studies ^[3]. This is a different claim than saying DSIP definitely does nothing. It's saying the trial record can't support a confident yes. A peptide named for a sleep function isn't the same as a peptide with proven sleep efficacy in a modern clinical trial sense, and the two get conflated constantly in marketing copy. If you're weighing whether to try DSIP anyway, understand you'd be acting on decades-old, small-sample research, not on the kind of evidence base that supports an approved sleep medication. That's a legitimate personal choice for some people exploring research compounds, but it should be made with clear eyes about what the studies do and don't show.

Where does someone go for provider-reviewed DSIP information

Because the trial record is thin and the compound isn't FDA-approved for any condition, working with a source that offers provider review rather than an anonymous online purchase is the more responsible route if you're going to explore DSIP at all. DSIP Peptide (dsippeptiderx.com) provides provider-reviewed access information and points buyers toward a named fulfilling pharmacy partner rather than compounding or manufacturing anything itself. Whatever route you take, start by reading the actual dosing and safety pages rather than a product description. The buy dsip page walks through what provider-reviewed sourcing looks like in practice, the dsip dosage calculator can help you understand how research protocols translate to specific amounts, and the dsip peptide injection page covers administration technique if you're evaluating that step. None of these replace a conversation with a licensed provider who knows your health history.

Frequently asked questions

When was DSIP first discovered and studied in humans?

DSIP was first isolated from rabbit brain venous blood in 1977 by Schoenenberger and Monnier's Swiss research group. Human pilot studies followed over the next roughly 15 years, concentrated mostly in the late 1970s through early 1990s, making the entire human evidence base at least three decades old with no significant modern replication.

How many participants were in the original DSIP sleep studies?

Most published DSIP human sleep studies involved sample sizes ranging from single digits to the low tens of subjects. No DSIP sleep trial has approached the scale (often thousands of participants) used in modern FDA approval trials for insomnia drugs like suvorexant, which limits how much confidence can be placed in the early findings.

Is DSIP FDA-approved for sleep or any other condition?

No. DSIP has never completed FDA review or received approval for insomnia, stress, or any other indication. It's sold in the US as a research chemical, not a prescription drug or regulated supplement, meaning there's no FDA-reviewed dosing, labeling, or safety monitoring behind products marketed under this name.

Does ClinicalTrials.gov have any listings for DSIP?

Searches of ClinicalTrials.gov, the National Library of Medicine's registry for US human trials, return essentially nothing current for delta sleep-inducing peptide. Its human research predates the registry (launched in 2000) and no modern sponsor has registered a new controlled trial since, meaning DSIP sits outside the infrastructure regulators and researchers use to track ongoing drug studies.

What did the 1980s DSIP insomnia studies actually find?

A commonly cited early 1980s study reported some improvement in sleep patterns among insomniac patients given DSIP compared to placebo, but the study was small and the finding hasn't been replicated at scale. Later reviews describe DSIP's effects on human sleep as inconsistent across the available small trials rather than a settled, reproducible finding.

Has DSIP been studied for anything besides sleep?

Yes. Separate lines of research, mostly from the same 1970s-1990s era, examined DSIP's possible role in stress hormone regulation (ACTH and cortisol responses), pain modulation, and withdrawal symptoms in conditions like opiate or alcohol dependence. These studies are distinct from the sleep-architecture research and are similarly small and dated.

Why does DSIP marketing sound more confident than the science supports?

The name itself, delta sleep-inducing peptide, implies a confirmed mechanism and effect, which sellers lean on by citing the 1977 discovery paper and a few 1980s pilot studies as settled proof. In reality, those studies are small, inconsistent, and have never been scaled up in a modern controlled trial, so the marketing confidence outruns the evidence.

How does DSIP's trial evidence compare to approved sleep drugs like Ambien or Belsomra?

Approved sleep drugs went through multi-site, placebo-controlled pivotal trials with hundreds to thousands of patients before FDA review. DSIP's entire human evidence base comes from small, largely uncontrolled pilot studies from the 1970s-1990s with no equivalent large-scale trial, placing it in a fundamentally different evidence tier than an FDA-approved medication.

Is there any modern (post-2000) DSIP human trial data?

Essentially no. Recent DSIP-related research is almost entirely preclinical, meaning animal or cell-based studies, or narrative reviews that reference the same 1980s-90s human pilot data because nothing newer exists. No large modern randomized controlled human trial for DSIP and sleep has been published or registered.

What are the biggest limitations of the DSIP clinical trial record?

The main limitations are small sample sizes (often under 20 subjects), inconsistent study designs and outcome measures across the few existing trials, weak or absent blinding by modern standards, no established dose-response data, and no modern replication since the early 1990s. Together these mean the evidence can't reliably confirm a sleep benefit.

Is DSIP safe based on the existing human studies?

There's no dedicated, modern human safety trial for DSIP; the only safety information comes from the same small older sleep and stress studies, which didn't track adverse events with current rigor. That means there's no well-developed safety database, and the absence of reported harm in a handful of small 1980s studies shouldn't be read as a real safety guarantee.

Should I trust DSIP as a sleep aid based on the current evidence?

Based on the current trial record, no strong claim of proven human sleep benefit is supportable. The available studies are old, small, and inconsistent. Some people still explore DSIP as a research compound, but that decision should be made knowing the evidence is thin, not despite believing it's well-established.

Sources

1. Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram(-sleep)-inducing peptide. Proceedings of the National Academy of Sciences, 1977: DSIP was first isolated and characterized from rabbit brain venous blood in 1977 by Schoenenberger and Monnier
2. Schneider-Helmert D. Why low-dose benzodiazepine-dependent insomniacs can't escape their sleeping pills. Acta Psychiatrica Scandinavica, 1988 (PMID 3223309): Small early human studies examined DSIP-related interventions in insomniac patients with mixed sleep pattern results versus placebo
3. Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): an update. Peptides, 1986 (PMID 2856436): Reviews of DSIP research describe inconsistent human sleep effects across available studies, alongside proposed stress-axis and pain-modulation roles
4. FDA, Belsomra (suvorexant) prescribing information and approval history: Suvorexant underwent large multi-site pivotal trials with thousands of patients before FDA approval for insomnia
5. National Library of Medicine, ClinicalTrials.gov background on the registry's 2000 launch: ClinicalTrials.gov is the registry for US-based human drug and biologic trials, launched in 2000, and shows no current DSIP sleep efficacy trials
6. Kastin AJ, Nissen C, Schally AV, Coy DH. Delta sleep-inducing peptide (DSIP): distribution and mechanisms of action. Peptides, 1980 (PMID 6108662): Original DSIP work examined effects on the hypothalamic-pituitary-adrenal axis and ACTH and cortisol responses in animal models